Compare ATRC & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATRC | CLDX |
|---|---|---|
| Founded | 2000 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.9B |
| IPO Year | 2005 | 2008 |
| Metric | ATRC | CLDX |
|---|---|---|
| Price | $36.74 | $25.68 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 10 |
| Target Price | ★ $52.22 | $44.10 |
| AVG Volume (30 Days) | 425.9K | ★ 738.8K |
| Earning Date | 02-11-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $518,304,999.00 | $2,599,000.00 |
| Revenue This Year | $16.90 | N/A |
| Revenue Next Year | $12.25 | $23.23 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 15.80 | N/A |
| 52 Week Low | $28.29 | $14.40 |
| 52 Week High | $43.18 | $30.50 |
| Indicator | ATRC | CLDX |
|---|---|---|
| Relative Strength Index (RSI) | 37.68 | 44.89 |
| Support Level | $38.68 | $25.15 |
| Resistance Level | $43.18 | $28.00 |
| Average True Range (ATR) | 1.48 | 1.22 |
| MACD | -0.53 | -0.10 |
| Stochastic Oscillator | 0.00 | 18.08 |
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.